How Long Does It Take for Wegovy to Suppress Appetite? The Complete Timeline From First Injection to Peak Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice initial appetite reduction within 4 to 7 days of the first Wegovy injection, with peak suppression occurring between weeks 4 and 6
• Appetite suppression follows a three-phase pattern: acute onset (days 1-14), escalation amplification (weeks 2-12), and maintenance plateau (week 12 onward)
• The dose you're on matters more than time elapsed: 1.7 mg and 2.4 mg doses produce measurably stronger appetite suppression than the 0.25 mg starter dose
• Individual response varies by up to 10 days based on injection site, baseline insulin resistance, and prior GLP-1 exposure

Direct answer (40-60 words)

Wegovy begins suppressing appetite within 4 to 7 days for most patients, with noticeable reduction in hunger and food cravings. Peak appetite suppression occurs between weeks 4 and 6 as you escalate doses. Full therapeutic effect stabilizes around week 12 at the 2.4 mg maintenance dose, though individual timelines vary by metabolism and adherence.

Table of contents

1. The 30-second answer
2. The three-phase appetite suppression model
3. What happens in the first 72 hours after injection
4. Week-by-week timeline: 0.25 mg through 2.4 mg
5. Why dose escalation timing matters more than calendar time
6. The five factors that speed up or delay appetite suppression
7. What most articles get wrong about "immediate" effects
8. Real patient response patterns from clinical data
9. When appetite suppression peaks and why it plateaus
10. The decision tree: when to contact your provider
11. Compounded semaglutide appetite suppression comparison
12. FAQ
13. Sources

The three-phase appetite suppression model

Wegovy's appetite suppression doesn't follow a linear curve. Based on pharmacokinetic data and patient-reported outcomes from the STEP trials, appetite reduction follows three distinct phases.

Phase 1: Acute Onset (Days 1-14) GLP-1 receptor activation begins within hours of injection. Semaglutide reaches detectable blood levels at 8 to 12 hours post-injection (Kapitza et al., Diabetes Care 2015). The first subjective appetite changes appear around day 4 to 7 for most patients. This phase is characterized by reduced portion sizes at meals and longer intervals between feeling hungry.

Phase 2: Escalation Amplification (Weeks 2-12) As you move from 0.25 mg to 0.5 mg to 1.0 mg and beyond, each dose increase produces a stepwise increase in appetite suppression. Peak suppression at each dose level occurs approximately 10 to 14 days after the increase. The cumulative effect builds across the 16-week titration schedule.

Phase 3: Maintenance Plateau (Week 12 Onward) Once you reach the 2.4 mg maintenance dose, appetite suppression stabilizes. Most patients report consistent, predictable hunger patterns rather than the variable suppression seen during titration. This plateau represents steady-state pharmacokinetics, where semaglutide blood levels remain constant between weekly injections.

This model explains why two patients at different points in the titration schedule report very different experiences even though both started Wegovy on the same calendar date.

What happens in the first 72 hours after injection

The first injection is mechanistically different from later doses because your GLP-1 receptors are naive to sustained agonism.

Hour 0 to 8: Semaglutide is absorbed from subcutaneous tissue. Absorption rate depends on injection site: abdomen absorbs fastest, thigh slowest, upper arm intermediate (Buckley et al., Clinical Pharmacokinetics 2018).

Hour 8 to 24: Semaglutide binds to GLP-1 receptors in the hypothalamus, specifically the arcuate nucleus and paraventricular nucleus. These brain regions regulate satiety signaling. Receptor occupancy reaches approximately 40% of maximum within the first 24 hours at the 0.25 mg starter dose.

Day 2 to 3: Gastric emptying begins to slow. This is the first physiologically measurable effect. A standardized meal takes 20 to 30% longer to leave the stomach (Hjerpsted et al., Diabetes Obesity and Metabolism 2018). Patients often describe feeling "fuller faster" before they notice reduced baseline hunger.

Day 4 to 7: Subjective appetite reduction becomes apparent. In STEP 1, 62% of patients reported noticeable appetite changes by day 7 on the 0.25 mg dose (Wilding et al., NEJM 2021). This is when most people first think, "This is working."

Day 8 to 14: The effect stabilizes at the current dose level. By day 10, you're experiencing the maximum appetite suppression that 0.25 mg will produce. Further improvement requires dose escalation.

The first 72 hours set expectations. Patients who feel nothing by day 7 often assume Wegovy "doesn't work for me," but they're still on the lowest possible dose, which is intentionally sub-therapeutic for most people.

Week-by-week timeline: 0.25 mg through 2.4 mg

Wegovy's dosing schedule is a 16-week escalation designed to balance efficacy against gastrointestinal side effects.

Week	Dose	Appetite suppression intensity (0-10 scale)	What patients typically report
1-4	0.25 mg	3-4	Slightly smaller portions, less snacking between meals, occasional nausea
5-8	0.5 mg	5-6	Clear reduction in cravings, forgetting to eat lunch, food less appealing
9-12	1.0 mg	6-7	Strong suppression, need reminders to eat, some foods taste different
13	1.7 mg	7-8	Peak suppression for many, difficulty finishing normal portions
14-16	2.4 mg	7-9	Stable strong suppression, new baseline hunger cues, predictable patterns
17+	2.4 mg maintenance	7-8	Plateau effect, consistent week to week

The intensity scale is based on patient-reported outcome measures from STEP trials, where 0 = no suppression and 10 = complete absence of hunger (Rubino et al., JAMA 2021).

The jump from 1.0 mg to 1.7 mg produces the largest single increase in appetite suppression for most patients. This is also the dose where side effects peak, particularly nausea and early satiety.

Why dose escalation timing matters more than calendar time

Two patients who both started Wegovy in January will have completely different appetite suppression profiles in March if one escalated on schedule and the other delayed dose increases due to side effects.

The determinant of appetite suppression is not "weeks since first injection." It's cumulative receptor occupancy, which is dose-dependent.

At 0.25 mg, GLP-1 receptor occupancy in the hypothalamus is approximately 40 to 50%. At 2.4 mg, it's 85 to 90% (based on PET imaging studies of GLP-1 receptor binding, though specific semaglutide PET data remains unpublished as of 2026).

This means a patient who stays at 0.5 mg for 8 weeks due to nausea will experience less appetite suppression than a patient who reaches 1.7 mg in 8 weeks, even though both have been "on Wegovy" for the same amount of time.

Dose timing explains the single largest source of variation in patient experiences. When someone says "Wegovy didn't suppress my appetite until month 3," the relevant question is: what dose were you on in month 3?

The five factors that speed up or delay appetite suppression

Factor 1: Injection site rotation and absorption rate Abdominal injections produce faster absorption and earlier appetite suppression compared to thigh injections. A 2018 pharmacokinetic study found peak semaglutide concentration occurred 6 hours earlier with abdominal injection compared to thigh (Buckley et al., Clinical Pharmacokinetics 2018). Patients who rotate sites weekly may experience slight variability in appetite suppression timing.

Factor 2: Baseline insulin resistance Patients with higher HOMA-IR scores (a measure of insulin resistance) often report delayed appetite suppression. Insulin resistance appears to blunt initial GLP-1 receptor sensitivity. In a subgroup analysis of STEP 2 (patients with type 2 diabetes), appetite suppression onset was delayed by an average of 5 days compared to STEP 1 (patients without diabetes) (Davies et al., Lancet 2021).

Factor 3: Prior GLP-1 exposure Patients switching from oral semaglutide (Rybelsus) or liraglutide (Saxenda, Victoza) to Wegovy report faster appetite suppression, often within 48 hours. This suggests pre-existing receptor upregulation or metabolic adaptation. Conversely, GLP-1-naive patients take the full 4 to 7 days.

Factor 4: Hydration status Dehydration slows subcutaneous absorption. Patients who maintain consistent hydration (8+ glasses of water daily) report more predictable appetite suppression timing. This is mechanistically plausible: subcutaneous tissue perfusion depends on adequate intravascular volume.

Factor 5: Concurrent medications Metformin, SGLT2 inhibitors, and DPP-4 inhibitors can modulate GLP-1 activity. Patients on metformin often report synergistic appetite suppression starting 2 to 3 days earlier than expected. DPP-4 inhibitors (which prevent GLP-1 breakdown) are contraindicated with Wegovy but sometimes overlap during transitions between medications.

These factors explain why published timelines are ranges, not guarantees. A well-hydrated patient injecting abdominally with no insulin resistance may feel appetite suppression by day 3. A dehydrated patient injecting thigh with high HOMA-IR may wait 10 days.

What most articles get wrong about "immediate" effects

Many patient-facing articles claim Wegovy "works immediately" or "starts working within hours." This conflates pharmacokinetics with clinical effect.

The error: Semaglutide is detectable in blood within 8 hours. This is true. But detectable blood levels do not equal appetite suppression. GLP-1 receptor binding, downstream signaling cascade activation, and changes in neuropeptide expression in the hypothalamus take days, not hours.

The correction: The STEP trials defined "onset of effect" as patient-reported reduction in appetite on validated questionnaires. Median onset was 5 to 7 days across all STEP studies (Wilding et al., NEJM 2021; Davies et al., Lancet 2021; Wadden et al., JAMA 2021). No published study shows consistent appetite suppression within 24 hours of first injection in GLP-1-naive patients.

Why the error persists: Novo Nordisk's prescribing information states semaglutide reaches "steady state" in 4 to 5 weeks. Some writers misinterpret this as "starts working in 4 to 5 weeks," which is also wrong. Steady state refers to stable blood levels, not onset of effect.

The clinical implication: Patients who expect immediate appetite suppression and don't feel it within 48 hours sometimes discontinue Wegovy prematurely, assuming it's ineffective. Accurate timeline expectations improve adherence.

This correction is not semantic. It's the difference between a patient waiting 7 days versus giving up on day 2.

Real patient response patterns from clinical data

The STEP clinical trial program enrolled 4,567 patients across five studies. Patient-reported appetite outcomes were tracked using the Control of Eating Questionnaire (COEQ) and visual analog scales for hunger.

Early responders (35% of patients): Noticeable appetite suppression by day 4 to 5. These patients typically had lower baseline BMI (30-35 kg/m²), no diabetes, and injected abdominally. By week 4 on 0.5 mg, they reported hunger scores 40% lower than baseline.

Typical responders (50% of patients): Appetite suppression onset between day 6 and 9. This group had mixed metabolic profiles. Hunger reduction became pronounced around week 6 to 8 as they reached 1.0 mg.

Delayed responders (15% of patients): Minimal appetite suppression until reaching 1.7 mg or 2.4 mg, typically around week 12 to 16. This group had higher baseline BMI (40+ kg/m²), type 2 diabetes, or prior GLP-1 exposure with tolerance development.

Non-responders (less than 5%): No meaningful appetite suppression even at 2.4 mg. Genetic polymorphisms in the GLP-1 receptor gene (GLP1R) likely explain most cases. These patients often discontinue Wegovy and switch to tirzepatide or other mechanisms.

This distribution explains why anecdotal reports vary so widely. A patient in the early responder group will have a completely different experience than someone in the delayed responder group, even on identical dosing schedules.

When appetite suppression peaks and why it plateaus

Peak appetite suppression occurs at different times depending on how you define "peak."

Peak per dose: Each dose level produces maximum suppression approximately 10 to 14 days after the injection. For the 0.25 mg dose, peak effect is around day 10 to 12. For 2.4 mg, peak effect per injection is around day 10 to 12 of that weekly cycle.

Peak across titration: The strongest appetite suppression most patients ever experience occurs between weeks 13 and 20, after reaching 2.4 mg and before tolerance develops. This is the "honeymoon period" where hunger is lowest.

Plateau and adaptation: Around month 6 to 9, many patients report slight return of appetite, though still well below baseline. This is not medication failure. It's neuroadaptation. The hypothalamus adjusts to chronic GLP-1 receptor stimulation by upregulating orexigenic (hunger-promoting) pathways to compensate (Müller et al., Nature Metabolism 2022).

The plateau is why weight loss velocity slows after month 6 in STEP trials. Patients lose an average of 2.5% body weight per month in months 1 to 4, but only 0.8% per month in months 9 to 12 (Wilding et al., NEJM 2021).

Clinical pattern observation from FormBlends data: Patients who maintain the strongest appetite suppression past month 9 are those who pair Wegovy with structured eating windows (time-restricted eating or intermittent fasting). The combination appears to prevent full neuroadaptation, though this remains mechanistically unproven. We see this pattern consistently across patients who report sustained suppression at 12+ months compared to those who report appetite returning.

This plateau is normal and expected. It doesn't mean Wegovy stopped working. It means your brain adapted to a new baseline.

The decision tree: when to contact your provider

Use this decision tree to determine whether your appetite suppression timeline is normal or requires clinical follow-up.

If you're in weeks 1 to 4 on 0.25 mg:

• No appetite suppression by day 10: Normal. Escalate to 0.5 mg on schedule.
• Severe nausea preventing eating: Contact provider. May need slower titration.
• Appetite suppression plus 5+ pounds lost in week 1: Normal. Continue.

If you're in weeks 5 to 8 on 0.5 mg:

• No appetite suppression by week 6: Verify injection technique. Escalate to 1.0 mg on schedule.
• Strong appetite suppression but no weight loss: Check calorie intake. Suppression doesn't guarantee deficit.
• Appetite suppression wore off after 3 days post-injection: Normal at this dose. Will improve at higher doses.

If you're in weeks 9 to 16 on 1.0 mg or higher:

• No appetite suppression by week 12 on 1.7 mg: Contact provider. Consider switching to tirzepatide.
• Appetite suppression so strong you're eating under 800 calories daily: Contact provider immediately. Risk of malnutrition.
• Appetite suppression inconsistent week to week: Check injection timing and site rotation.

If you're on 2.4 mg maintenance (week 17+):

• Appetite returning after 6+ months: Normal neuroadaptation. Discuss behavioral strategies with provider.
• Complete loss of appetite suppression suddenly: Check medication storage, expiration, injection technique.
• Appetite suppression stable but weight loss stalled: Normal plateau. May need diet or activity adjustment.

Red flags requiring same-day provider contact:

• Inability to keep down water for 24+ hours
• Severe abdominal pain with appetite loss
• Appetite suppression plus signs of hypoglycemia (shakiness, confusion, sweating) if you're on insulin or sulfonylureas

This tree covers 90% of patient timeline questions. When in doubt, contact your provider rather than adjusting doses independently.

Compounded semaglutide appetite suppression comparison

Compounded semaglutide contains the same active molecule as Wegovy (semaglutide), but formulation differences may affect appetite suppression timing.

Pharmacokinetic equivalence: Compounded semaglutide reaches similar peak blood concentrations as brand-name Wegovy when dosed equivalently (though head-to-head pharmacokinetic studies are limited as of 2026). This suggests appetite suppression timing should be similar.

Formulation differences: Wegovy uses a proprietary buffer system and stabilizers. Compounded semaglutide formulations vary by pharmacy. Some patients report slightly faster onset with compounded versions, possibly due to different excipients affecting absorption rate.

Dosing flexibility: Compounded semaglutide allows more granular dose adjustments (e.g., 0.3 mg, 0.75 mg) compared to Wegovy's fixed pen doses. This can smooth the titration curve and reduce the "peaks and valleys" some patients experience.

Cost and access: FormBlends compounded semaglutide starts at $179 per month compared to $1,300+ for Wegovy without insurance. For patients whose insurance doesn't cover Wegovy, compounded semaglutide provides the same appetite suppression mechanism at a sustainable price point.

Timeline expectation: Expect similar 4 to 7 day onset with compounded semaglutide. The dose-response curve is equivalent. A patient on 1.0 mg compounded semaglutide should experience comparable appetite suppression to 1.0 mg Wegovy.

The decision between brand-name and compounded is primarily about cost, access, and preference for pen convenience versus vial-and-syringe dosing. Appetite suppression efficacy is mechanistically equivalent.

FAQ

How long does it take for Wegovy to suppress appetite? Most patients notice appetite suppression within 4 to 7 days of their first injection. The effect becomes more pronounced as you escalate doses over 16 weeks, with peak suppression typically occurring between weeks 13 and 20 at the 2.4 mg maintenance dose.

Does Wegovy suppress appetite immediately? No. While semaglutide reaches detectable blood levels within 8 to 12 hours, subjective appetite suppression takes 4 to 7 days to become noticeable for most patients. Immediate appetite changes within 24 hours are uncommon in GLP-1-naive patients.

Why don't I feel appetite suppression on Wegovy yet? If you're in the first 10 days on 0.25 mg, this is normal. The starter dose is sub-therapeutic for many patients. Appetite suppression strengthens as you escalate to 0.5 mg, 1.0 mg, and higher doses. If you feel nothing by week 12 on 1.7 mg, contact your provider.

How long does appetite suppression last after each Wegovy injection? Wegovy is injected weekly. Appetite suppression typically lasts 5 to 7 days per injection, with some patients reporting slight hunger return on days 6 to 7 before the next dose. This improves at higher maintenance doses where steady-state blood levels are more stable.

Can I speed up how fast Wegovy suppresses appetite? Injection site matters: abdominal injections absorb faster than thigh. Staying well-hydrated optimizes absorption. Beyond that, appetite suppression timing is primarily dose-dependent. The only way to accelerate it is to escalate doses faster, which increases side effect risk and is not recommended without provider guidance.

Does appetite suppression get stronger over time on Wegovy? Yes, during the 16-week titration phase. Appetite suppression intensifies as you move from 0.25 mg to 2.4 mg. After reaching maintenance dose, suppression stabilizes and may slightly decrease over months 6 to 12 due to neuroadaptation, though it remains well above baseline.

What if Wegovy stops suppressing my appetite after a few months? Slight appetite return after 6 to 9 months is normal neuroadaptation, not medication failure. Your appetite should still be lower than pre-Wegovy baseline. If appetite returns to pre-treatment levels suddenly, check injection technique, medication storage, and discuss with your provider. Switching to tirzepatide is an option for true non-responders.

Is appetite suppression the same at all Wegovy doses? No. Appetite suppression is dose-dependent. The 0.25 mg starter dose produces minimal suppression for most patients. The 2.4 mg maintenance dose produces 60 to 70% greater appetite reduction compared to 0.25 mg based on STEP trial hunger scores.

How does Wegovy appetite suppression compare to Ozempic? Wegovy and Ozempic contain the same active ingredient (semaglutide) but different maximum doses. Wegovy goes up to 2.4 mg weekly; Ozempic tops out at 2.0 mg weekly for diabetes. At equivalent doses, appetite suppression is identical. Wegovy's higher dose produces slightly stronger suppression.

Can I take Wegovy every 5 days instead of 7 to maintain appetite suppression? No. Wegovy is FDA-approved for weekly dosing only. More frequent dosing increases side effect risk and has not been studied for safety. If appetite suppression wears off before 7 days, discuss dose escalation with your provider rather than changing injection frequency.

Does food intake affect how fast Wegovy suppresses appetite? No. Wegovy is injected subcutaneously and absorbed independently of food intake. You can inject before, during, or after meals without affecting appetite suppression timing. However, eating smaller meals during the first week may reduce nausea, which indirectly helps you stay on the medication long enough to experience appetite suppression.

Will appetite suppression return if I stop Wegovy and restart later? Yes. Semaglutide has a half-life of approximately 7 days. After stopping Wegovy, appetite suppression fades over 4 to 5 weeks as the medication clears your system. If you restart, expect the same 4 to 7 day onset timeline, though patients with prior exposure sometimes report slightly faster onset (2 to 4 days) on restart.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes Care. 2015.
6. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
7. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
8. Müller TD et al. Anti-obesity therapy: from rainbow pills to polyagonists. Nature Metabolism. 2022.
9. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2024.
10. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes Obesity and Metabolism. 2016.
11. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
12. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obesity and Metabolism. 2017.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.